{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:58:50Z","timestamp":1760367530326},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10165-010-0366-7","type":"journal-article","created":{"date-parts":[[2010,10,15]],"date-time":"2010-10-15T00:35:45Z","timestamp":1287102945000},"page":"122-133","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)"],"prefix":"10.1093","volume":"21","author":[{"given":"Hisashi","family":"Yamanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Momohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Hanami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yunoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,10,16]]},"reference":[{"key":"366_CR1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","volume":"423","author":"GS Firestein","year":"2003","unstructured":"Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356\u201361.","journal-title":"Nature"},{"key":"366_CR2","unstructured":"Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2004;43[Suppl 3]:17\u201323."},{"key":"366_CR3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.090125","volume":"82","author":"EC Keystone","year":"2009","unstructured":"Keystone EC. Clinical implications of understanding radiographic findings in relation to clinical outcomes in rheumatoid arthritis. J Rheumatol Suppl. 2009;82:11\u20136.","journal-title":"J Rheumatol Suppl"},{"key":"366_CR4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"M Feldmann","year":"1996","unstructured":"Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397\u2013440.","journal-title":"Annu Rev Immunol"},{"key":"366_CR5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105\u201310.","journal-title":"Lancet"},{"key":"366_CR6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141\u20137.","journal-title":"N Engl J Med"},{"key":"366_CR7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.20982","volume":"52","author":"JS Smolen","year":"2005","unstructured":"Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52:1020\u201330.","journal-title":"Arthritis Rheum"},{"key":"366_CR8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675\u201381.","journal-title":"Lancet"},{"key":"366_CR9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","volume":"372","author":"P Emery","year":"2008","unstructured":"Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375\u201382.","journal-title":"Lancet"},{"key":"366_CR10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/13543784.17.3.349","volume":"17","author":"GD Kalliolias","year":"2008","unstructured":"Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs. 2008;17:349\u201359.","journal-title":"Expert Opin Investig Drugs"},{"key":"366_CR11","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/41.9.972","volume":"41","author":"SB Abramson","year":"2002","unstructured":"Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford). 2002;41:972\u201380.","journal-title":"Rheumatology (Oxford)"},{"key":"366_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","volume":"23","author":"T Kishimoto","year":"2005","unstructured":"Kishimoto T. Interleukin-6: from basic science to medicine\u201340\u00a0years in immunology. Annu Rev Immunol. 2005;23:1\u201321.","journal-title":"Annu Rev Immunol"},{"key":"366_CR13","first-page":"1426","volume":"30","author":"N Nishimoto","year":"2003","unstructured":"Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I\/II clinical study. J Rheumatol. 2003;30:1426\u201335.","journal-title":"J Rheumatol"},{"key":"366_CR14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","volume":"50","author":"N Nishimoto","year":"2004","unstructured":"Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761\u20139.","journal-title":"Arthritis Rheum"},{"key":"366_CR15","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817\u201329.","journal-title":"Arthritis Rheum"},{"key":"366_CR16","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"66","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162\u20137.","journal-title":"Ann Rheum Dis"},{"key":"366_CR17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987\u201397.","journal-title":"Lancet"},{"key":"366_CR18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"366_CR19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10165-009-0197-6","volume":"19","author":"R Koike","year":"2009","unstructured":"Koike R, Harigai M, Atsumi T, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009;19:351\u20137.","journal-title":"Mod Rheumatol"},{"key":"366_CR20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2018t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44\u20138.","journal-title":"Arthritis Rheum"},{"key":"366_CR21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137\u201345.","journal-title":"Arthritis Rheum"},{"key":"366_CR22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.11465","volume":"49","author":"Y Matsuda","year":"2003","unstructured":"Matsuda Y, Singh G, Yamanaka H, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49:784\u20138.","journal-title":"Arthritis Rheum"},{"key":"366_CR23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM Gestel van","year":"1996","unstructured":"van Gestel AM, Prevoo ML, van \u2018t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34\u201340.","journal-title":"Arthritis Rheum"},{"key":"366_CR24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s10165-006-0546-7","volume":"17","author":"H Yamanaka","year":"2007","unstructured":"Yamanaka H, Inoue E, Tanaka E, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol. 2007;17:98\u2013105.","journal-title":"Mod Rheumatol"},{"key":"366_CR25","unstructured":"Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol. 2010;343\u201352."},{"issue":"Suppl 2","key":"366_CR26","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar1916","volume":"8","author":"T Kishimoto","year":"2006","unstructured":"Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther. 2006;8[Suppl 2]:S2.","journal-title":"Arthritis Res Ther"},{"key":"366_CR27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.080791","volume":"36","author":"T Koike","year":"2009","unstructured":"Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898\u2013906.","journal-title":"J Rheumatol"},{"key":"366_CR28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865\u201376.","journal-title":"Ann Intern Med"},{"key":"366_CR29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114\u201323.","journal-title":"N Engl J Med"},{"key":"366_CR30","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390\u2013400.","journal-title":"Arthritis Rheum"},{"key":"366_CR31","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793\u2013806.","journal-title":"Arthritis Rheum"},{"key":"366_CR32","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968\u201380.","journal-title":"Arthritis Rheum"},{"key":"366_CR33","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves randomised placebo-controlled trial biologicals: results from a 24-week multicentre arthritis refractory to anti-tumour necrosis factor treatment outcomes in patients with rheumatoid. Ann Rheum Dis. 2008;67:1516\u201323.","journal-title":"Ann Rheum Dis"},{"key":"366_CR34","first-page":"1521","volume":"163","author":"P Charles","year":"1999","unstructured":"Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163:1521\u20138.","journal-title":"J Immunol"},{"key":"366_CR35","first-page":"225","volume":"6","author":"DM Butler","year":"1995","unstructured":"Butler DM, Maini RN, Feldmann M, et al. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti-TNF-alpha antibody with the IL-1 receptor antagonist. Eur Cytokine Netw. 1995;6:225\u201330.","journal-title":"Eur Cytokine Netw"},{"key":"366_CR36","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861\u201374.","journal-title":"Lancet"},{"key":"366_CR37","first-page":"1","volume":"74","author":"T Kishimoto","year":"1989","unstructured":"Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1\u201310.","journal-title":"Blood"},{"key":"366_CR38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","volume":"43","author":"JJ Anderson","year":"2000","unstructured":"Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000;43:22\u20139.","journal-title":"Arthritis Rheum"},{"key":"366_CR39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3899\/jrheum.080930","volume":"36","author":"I Nakamura","year":"2009","unstructured":"Nakamura I, Omata Y, Naito M, Ito K. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J Rheumatol. 2009;36:459\u201360.","journal-title":"J Rheumatol"},{"key":"366_CR40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","volume":"67","author":"T Takeuchi","year":"2008","unstructured":"Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189\u201394.","journal-title":"Ann Rheum Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-010-0366-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:27:35Z","timestamp":1646843255000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-010-0366-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,16]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1007\/s10165-010-0366-7","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,16]]}}}